MARKET

TAK

TAK

Takeda Pharm
NYSE
13.89
-0.30
-2.11%
After Hours: 13.87 -0.02 -0.14% 16:06 03/28 EDT
OPEN
13.94
PREV CLOSE
14.19
HIGH
13.96
LOW
13.82
VOLUME
1.48M
TURNOVER
0
52 WEEK HIGH
17.15
52 WEEK LOW
12.90
MARKET CAP
43.58B
P/E (TTM)
34.74
1D
5D
1M
3M
1Y
5Y
Takeda Reveals Board Candidates for Shareholders’ Vote
TipRanks · 1d ago
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
Takeda's 'In Their Shoes' initiative illuminates the daily struggles of IBD patients in the UAE. The initiative aims to raise awareness of the difficult symptoms of Inflammatory Bowel Disease. The 24-hour simulation generated a deeper understanding of how the disease affects patients. More than 10 million people worldwide live with IBD.
PR Newswire · 2d ago
2 More Potential Biotech Buyout Targets
Oncology is projected to reach $375 billion in sales by 2027. The oncology space continues to be a hot and active area for M&A activity. Exelixis is one of two smaller companies that appear to be logical buyout targets for larger companies. The company is a mid-cap oncologist with a strong pipeline.
Seeking Alpha · 3d ago
Weekly Report: what happened at TAK last week (0318-0322)?
Weekly Report · 4d ago
Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S.
Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S. FDA greenlighted a Phase 2 trial to investigate oral kinase inhibitor alisertib in patients with breast cancer. Puma Biotechnology plans to start ALISCA-Breast1 in H2 2024.
Seeking Alpha · 03/20 14:06
*Scilex Holding Co Announces a Settlement Agreement With Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA With the FDA Seeking to Expand the Label for Its FDA-Approved Liquid Colchicine Pdt, Gloperba
Dow Jones · 03/20 13:01
Takeda : FDA Approves SNDA For Iclusig In Adult Patients With Newly Diagnosed Ph+ ALL
NASDAQ · 03/20 01:37
Centogene, Takeda extend diagnostic partnership
Healthcare Centogene, Takeda extend diagnostic partnership. German biotech will continue to provide its testing solutions to the Japanese pharma giant. The two companies will work together to diagnose patients with inherited metabolic diseases. CNTG and TAK first established a partnership in 2015.
Seeking Alpha · 03/19 11:41
More
About TAK
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Webull offers Takeda Pharmaceutical Co Ltd (ADR) stock information, including NYSE: TAK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TAK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TAK stock methods without spending real money on the virtual paper trading platform.